Aptose Biosciences Inc.

2.63+0.1300+5.20%Vol 11.59K1Y Perf -72.22%
Oct 4th, 2023 15:59 DELAYED
BID2.57 ASK3.03
Open2.62 Previous Close2.50
Pre-Market- After-Market2.68
 - -  0.05 1.90%
Target Price
8.00 
Analyst Rating
Strong Buy 1.17
Potential %
204.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.39 
Earnings Rating
Strong Sell
Market Cap17.15M 
Earnings Date
7th Nov 2023
Alpha-0.03 Standard Deviation0.26
Beta1.44 

Today's Price Range

2.582.74

52W Range

2.5011.85

5 Year PE Ratio Range

-7.40-2.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.71%
1 Month
-34.90%
3 Months
-43.92%
6 Months
-70.78%
1 Year
-72.22%
3 Years
-97.04%
5 Years
-92.75%
10 Years
-

TickerPriceChg.Chg.%
APTO2.630.13005.20
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
5.40
5.50
0.00
0.01
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-2.09-2.27-8.61
Q01 2023-1.80-2.25-25.00
Q04 2022-1.65-1.650.00
Q03 2022-1.80-1.658.33
Q02 2022-1.95-1.6515.38
Q01 2022-2.25-1.8020.00
Q04 2021-0.18-0.27-50.00
Q03 2021-0.17-0.1323.53
Earnings Per EndEstimateRevision %Trend
9/2023 QR-2.16-24.14Negative
12/2023 QR-2.07-18.29Negative
12/2023 FY-8.65-27.77Negative
12/2024 FY-7.147.27Positive
Next Report Date7th Nov 2023
Estimated EPS Next Report-2.16
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume11.59K
Shares Outstanding6.52K
Shares Float5.87M
Trades Count125
Dollar Volume30.48K
Avg. Volume37.45K
Avg. Weekly Volume41.33K
Avg. Monthly Volume32.80K
Avg. Quarterly Volume38.22K

Aptose Biosciences Inc. (NASDAQ: APTO) stock closed at 2.63 per share at the end of the most recent trading day (a 5.2% change compared to the prior day closing price) with a volume of 11.59K shares and market capitalization of 17.14M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 41 people. Aptose Biosciences Inc. CEO is William G. Rice.

The one-year performance of Aptose Biosciences Inc. stock is -72.22%, while year-to-date (YTD) performance is -69.77%. APTO stock has a five-year performance of -92.75%. Its 52-week range is between 2.5 and 11.85, which gives APTO stock a 52-week price range ratio of 1.39%

Aptose Biosciences Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -80.56%, a ROC of -82.89% and a ROE of -92.09%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aptose Biosciences Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.16 for the next earnings report. Aptose Biosciences Inc.’s next earnings report date is 07th Nov 2023.

The consensus rating of Wall Street analysts for Aptose Biosciences Inc. is Strong Buy (1.17), with a target price of $8, which is +204.18% compared to the current price. The earnings rating for Aptose Biosciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptose Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptose Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.10, ATR14 : 0.22, CCI20 : -149.75, Chaikin Money Flow : -0.66, MACD : -0.33, Money Flow Index : 18.51, ROC : -24.01, RSI : 19.66, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 11.61, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptose Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.17
Strong Buy
1.17

Aptose Biosciences Inc.

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.

CEO: William G. Rice

Telephone: +1 650 718-5028

Address: 251 Consumers Road,Suite 1105, Toronto M2J 4R3, ON, CA

Number of employees: 41

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

 

TipRanks News for APTO


News

Stocktwits